Table 2.
Description of All Recorded VTs and PVCs From the Prospective Case Series Study
| Case # | Sex | Age, y | Etiology | Epi/Endo Procedure | VT | Characteristics of VT morphology |
|---|---|---|---|---|---|---|
| 1 | M | 73.8 | ICM | Endo | VT1 | RB/Indeterminate axis/Tran V5‐V6/CL 520 ms |
| 2 | M | 80.1 | NICM | Endo and Epi | VT1 | RB/Inferior axis/Positive V1‐V6/CL 500 ms |
| VT2 | RB/Superior axis/Tran V4/CL 425 ms | |||||
| 3 | M | 43.4 | ARVC | Epi and Endo | PVC1 | LB/Superior axis/Negative V1‐V6/NA |
| PVC2 | LB/Inferior axis/Tran V3/NA | |||||
| PVC3 | LB/Superior axis/Tran V4/NA | |||||
| 4 | M | 63.1 | ARVD | Epi | VT1 | RB/Inferior axis/Positive V1‐V6/CL 367 ms |
| 5 | M | 77.0 | ICM | Endo | VT1 | RB/Indeterminate axis/Tran V2/CL 551 ms |
| 6 | M | 76.8 | ICM | Endo | VT1 | RB/Indeterminate axis/Tran V4‐V5/CL 523 ms |
| VT2 | RB/Superior axis/Tran V4/CL 423 ms | |||||
| VT3 | RB/Superior axis/Tran V5‐V6/CL 408 ms | |||||
| 7 | M | 81.2 | ICM | Endo | VT1 | LB/Superior axis/Trans V5/CL 420 ms |
| VT2 | RB/Superior axis/Trans V2‐V3/CL 270 ms | |||||
| 8 | M | 72.9 | ICM | Endo | VT1 | RB/Superior axis/Positive V1‐V6/CL 528 ms |
| VT2 | LB/Superior axis/Trans V4‐V5/CL 438 ms | |||||
| VT3 | RB/Superior axis/Trans V3/CL 474 ms | |||||
| 9 | M | 73.9 | ICM | Endo | VT1 | LB/Indeterminate axis/Tran V2/CL 241 ms |
| VT2 | RB/Indeterminate axis/Tran V4‐V5/CL 303 ms | |||||
| 10 | M | 64.6 | ICM | Endo | VT1 | LB/Inferior axis/Tran V5/CL 360 ms |
| 11 | M | 53.0 | NICM | Endo | VT1 | RB/Superior axis/Tran V2‐V3/CL 341 ms |
| VT2 | LB/Inferior axis/Tran V2‐V3/CL 299 ms | |||||
| VT3 | RB/Superior axis/Tran V2‐V3/CL 299 ms | |||||
| 12 | M | 24.2 | ARVC | Epi | … | No‐inducible VT |
| 13 | M | 69.3 | ICM | Endo | VT1 | LB/Inferior axis/Tran V3/CL 281 ms |
| 14 | M | 52.6 | ARVC | Epi and Endo | PVC1 | LB/Inferior axis/Tran V3‐V4/NA |
| 15 | M | 73.7 | NICM | LV Endo | VT1 | LB/Inferior axis/Tran V3/460 ms |
| VT2 | RB/Inferior axis/Positive V1‐V6/460 ms | |||||
| VT3 | RB/Indeterminate axis/Positive V1‐V6/490 ms | |||||
| 16 | M | 25.6 | ICM | Endo | VT1 | LB/Superior axis/qs in V1, biphasic in V2‐V3, and negative in V4‐V6/280 ms |
| VT2 | RB/Superior axis/Tran V4‐V5/CL 270 ms | |||||
| VT3 | LB/Indeterminate axis/ Tran V3‐V4/CL 400 ms | |||||
| 17 | M | 62.0 | ICM | Endo | VT1 | RB/Superior axis/Tran V2/CL 370 ms |
| VT2 | RB/Inferior axis/Positive V1‐V6/CL 330 ms | |||||
| VT3 | RB/Superior axis/Tran V3/CL 280 ms | |||||
| 18 | F | 22.2 | ARVC | Epi and Endo | PVC1 | LB/Inferior axis/Tran V3/NA |
| PVC2 | RB/Superior axis/Negative V1‐V6/NA | |||||
| 19 | F | 59.3 | ARVC | Epi and Endo | VT1 | LB/Superior axis/Negative V1‐V6/CL 318 ms |
| VT2 | LB/Indeterminate axis/Tran V6/CL 363 ms | |||||
| VT3 | LB/Inferior axis/Tran V6/CL 258 ms | |||||
| 20 | M | 61.4 | CS | Endo | VT1 | LB/Inferior axis/Tran V4/CL 270 ms |
| VT2 | RB/Inferior axis/Positive V1‐V6/CL 260 ms | |||||
| VT3 | LB/Indeterminate axis/Tran V2‐V3/CL 292 | |||||
| VT4 | RB/Superior axis/Tran V6/CL 249 ms | |||||
| VT5 | RB/Superior axis/Tran V5/CL 299ms | |||||
| VT6 | RB/Superior axis/Positive V1‐V6/CL 226 ms | |||||
| 21 | M | 74.9 | ICM | Endo | VT1 | RB/Indeterminate axis/Tran V4/CL 460 ms |
| VT2 | RB/Inferior axis/Tran V4/CL 335 ms | |||||
| 22 | M | 82.8 | ICM | Epi | VT1 | RB/Indeterminate axis/Tran V2/CL 400 ms |
| 23 | M | 74.1 | ICM | Endo | VT1 | LB/Inferior axis/Tran V5/CL 393 ms |
| VT2 | RB/Superior axis/Positive V1‐V6/CL 326 ms |
Description of ventricular tachycardia morphology: ventricular tachycardia morphology/axis based on 3 leads (inferior axis (positive in II, III, augmented Vector Foot leads), Superior axis (negative in II, III, augmented Vector Foot leads), Indeterminate axis)/QRS transition zone/cycle length; NA indicates that the cycle length was not definitely identified.
ARVC, arrhythmogenic right ventricular cardiomyopathy; ARVD, arrhythmogenic right ventricular dysplasia; aVF, augmented Vector Foot; CL, cycle length; CS, cardiac sarcoid; Endo, endocardial ablation procedure; Epi, epicardial ablation procedure; ICM, ischemic cardiomyopathy; LB, left bundle; LV, left ventricular; M, male; F, female; NICM, non‐ischemic cardiomyopathy; PVC, premature ventricular contraction; RB, right bundle; RV, right ventricular; and VT, ventricular tachycardia.